🇺🇸 l-LV in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 14

Most-reported reactions

1. Neutropenia — 4 reports (28.57%)
2. Decreased Appetite — 2 reports (14.29%)
3. Altered State Of Consciousness — 1 report (7.14%)
4. Amylase Increased — 1 report (7.14%)
5. Blood Fibrinogen Increased — 1 report (7.14%)
6. Dehydration — 1 report (7.14%)
7. Gingival Bleeding — 1 report (7.14%)
8. Hyperammonaemia — 1 report (7.14%)
9. Hyperammonaemic Encephalopathy — 1 report (7.14%)
10. Hyperhidrosis — 1 report (7.14%)

Source database →

Frequently asked questions

Is l-LV approved in United States?

l-LV does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for l-LV in United States?

EPS Corporation is the originator. The local marketing authorisation holder may differ — check the official source linked above.